Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world predictive model study of dorzagliatin target glycemic control in type 2 diabetes
ChiCTR2400079946Phase 4Not yet recruiting
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dorzagliatin in type 2 diabetes mellitus (T2DM), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoints: HbA1c at 52 weeks, fasting blood glucose at 52 weeks and 2 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400079946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079946.